Alba Aina Castells

Dr. Alba Aina Castells

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Biomaterials
Verified
Journal Article
Closed access
ZÁZaida Álvarez
Zaida Álvarez
OCOscar Castaño
Oscar Castaño
ACAlba Aina Castells
Alba Aina Castells
MTMiguel Angel Mateos Timoneda
Miguel Angel Mateos Timoneda
JPJosep A. Planell
Josep A. Planell
SASoledad Alcantara
Soledad Alcantara

11 February 2020 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
APAinhoa Pascual‐Alonso
Ainhoa Pascual‐Alonso
LBLaura Blasco
Laura Blasco
SVSilvia Vidal
Silvia Vidal
EGEsther Gean
Esther Gean
PRPatricia Rubio
Patricia Rubio
JAJudith Armstrong
Judith Armstrong

Verified
Journal Article
Open access
PDF file
AOAlfonso Oyarzábal
Alfonso Oyarzábal
CXClara Xiol
Clara Xiol
ACAlba Aina Castells
Alba Aina Castells
CGCristina Grau
Cristina Grau
MOMar O’callaghan
Mar O’callaghan
AGAngels García-Cazorla
Angels García-Cazorla
Rett syndrome, a serious neurodevelopmental disorder, has been associated with an altered expression of different synaptic-related proteins and aberrant glutamatergic and γ-aminobutyric acid (GABA)ergic neurotransmission. Despite its severity, it lacks a therapeutic option. Through this work we aimed to define the relationship between MeCP2 and GABAA.-A1 receptor expression, emphasizing the time dependence of such relationship. For this, we analyzed the expression of the ionotropic receptor subunit in different MeCP2 gene-dosage and developmental conditions, in cells lines, and in primary cultured neurons, as well as in different developmental stages of a Rett mouse model. Further, RNAseq and systems biology analysis was performed from post-mortem brain biopsies of Rett patients. We observed that the modulation of the MeCP2 expression in cellular models (both Neuro2a (N2A) cells and primary neuronal cultures) revealed a MeCP2 positive effect on the GABAA.-A1 receptor subunit expression, which did not occur in other proteins such as KCC2 (Potassium-chloride channel, member 5). In the Mecp2+/− mouse brain, both the KCC2 and GABA subunits expression were developmentally regulated, with a decreased expression during the pre-symptomatic stage, while the expression was variable in the adult symptomatic mice. Finally, the expression of the gamma-aminobutyric acid (GABA) receptor-related synaptic proteins from the postmortem brain biopsies of two Rett patients was evaluated, specifically revealing the GABA A1R subunit overexpression. The identification of the molecular changes along with the Rett syndrome prodromic stages strongly endorses the importance of time frame when addressing this disease, supporting the need for a neurotransmission-targeted early therapeutic intervention.

24 June 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ACAlba Aina Castells
Alba Aina Castells
DGDaniela Gueraldi
Daniela Gueraldi
RBRafel Balada
Rafel Balada
ATAlba Tristán-Noguero
Alba Tristán-Noguero
ECElisenda Cortès-Saladelafont
Elisenda Cortès-Saladelafont
ÀGÀngels Garcia-Cazorla
Àngels Garcia-Cazorla
Patients with inborn errors of amino acid metabolism frequently show neuropsychiatric symptoms despite accurate metabolic control. This study aimed to gain insight into the underlying mechanisms of neural dysfunction. Here we analyzed the expression of brain-derived neurotrophic factor (BDNF) and 10 genes required for correct brain functioning in plasma and blood of patients with Urea Cycle Disorders (UCD), Maple Syrup Urine Disease (MSUD) and controls. Receiver-operating characteristic (ROC) analysis was used to evaluate sensitivity and specificity of potential biomarkers. CACNA2D2 (α2δ2 subunit of voltage-gated calcium channels) and MECP2 (methyl-CpG binding protein 2) mRNA and protein showed an excellent neural function biomarker signature (AUC ≥ 0,925) for recognition of MSUD. THBS3 (thrombospondin 3) mRNA and AABA gave a very good biomarker signature (AUC 0,911) for executive-attention deficits. THBS3, LIN28A mRNA, and alanine showed a perfect biomarker signature (AUC 1) for behavioral and mood disorders. Finally, a panel of BDNF protein and at least two large neural AAs showed a perfect biomarker signature (AUC 1) for recognition of psychomotor delay, pointing to excessive protein restriction as central causative of psychomotor delay. To conclude, our study has identified promising biomarker panels for neural function evaluation, providing a base for future studies with larger samples.

17 January 2020 in Pediatric Research
Verified
Journal Article
Closed access
RBRafael Balada
Rafael Balada
CTCristian Tebé
Cristian Tebé
MLMarisol León
Marisol León
GAGemma Arca
Gemma Arca
MAMiguel Alsina
Miguel Alsina
AGAlfredo Garcia-Alix
Alfredo Garcia-Alix

3 February 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
ACAlba Aina Castells
Alba Aina Castells
RBRafel Balada
Rafel Balada
ATAlba Tristán-Noguero
Alba Tristán-Noguero
MOMar O’callaghan
Mar O’callaghan
ECElisenda Cortès-Saladelafont
Elisenda Cortès-Saladelafont
SASoledad Alcantara
Soledad Alcantara
Methyl-CpG-binding protein 2 (MeCP2) is an X-linked epigenetic modulator whose dosage is critical for neural development and function. Loss-of-function mutations in MECP2 cause Rett Syndrome (RTT, OMIM #312750) while duplications in the Xq28 locus containing MECP2 and Interleukin-1 receptor-associated kinase 1 (IRAK1) cause MECP2 duplication syndrome (MDS, OMIM #300260). Both are rare neurodevelopmental disorders that share clinical symptoms, including intellectual disability, loss of speech, hand stereotypies, vasomotor deficits and seizures. The main objective of this exploratory study is to identify novel signaling pathways and potential quantitative biomarkers that could aid early diagnosis and/or the monitoring of disease progression in clinical trials. We analyzed by RT-PCR gene expression in whole blood and microRNA (miRNA) expression in plasma, in a cohort of 20 females with Rett syndrome, 2 males with MECP2 duplication syndrome and 28 healthy controls, and correlated RNA expression with disease and clinical parameters. We have identified a set of potential biomarker panels for RTT diagnostic and disease stratification of patients with microcephaly and vasomotor deficits. Our study sets the basis for larger studies leading to the identification of specific miRNA signatures for early RTT detection, stratification, disease progression and segregation from other neurodevelopmental disorders. Nevertheless, these data will require verification and validation in further studies with larger sample size including a whole range of ages.